HC Wainwright Comments on BioCardia FY2025 Earnings

BioCardia, Inc. (NASDAQ:BCDA) – Research analysts at HC Wainwright issued their FY2025 earnings per share (EPS) estimates for BioCardia in a report released on Monday, September 22nd. HC Wainwright analyst J. Pantginis expects that the company will post earnings of ($1.38) per share for the year. HC Wainwright has a “Buy” rating and a $25.00 price objective on the stock. The consensus estimate for BioCardia’s current full-year earnings is ($3.52) per share. HC Wainwright also issued estimates for BioCardia’s FY2026 earnings at ($1.25) EPS, FY2027 earnings at ($1.33) EPS and FY2028 earnings at ($0.92) EPS.

Separately, Zacks Research upgraded BioCardia to a “hold” rating in a research report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, BioCardia currently has a consensus rating of “Buy” and a consensus target price of $25.00.

BioCardia Stock Performance

BCDA opened at $1.41 on Wednesday. The business’s fifty day moving average is $1.92 and its two-hundred day moving average is $2.15. The company has a market cap of $8.19 million, a price-to-earnings ratio of -0.76 and a beta of 0.85. BioCardia has a one year low of $1.00 and a one year high of $3.20.

BioCardia (NASDAQ:BCDA) last posted its earnings results on Monday, August 11th. The company reported ($0.40) EPS for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.10.

Hedge Funds Weigh In On BioCardia

Large investors have recently added to or reduced their stakes in the business. Cetera Investment Advisers purchased a new position in BioCardia during the second quarter worth about $40,000. Brown Advisory Inc. purchased a new position in BioCardia during the first quarter worth about $90,000. Finally, CM Management LLC lifted its position in BioCardia by 200.0% during the first quarter. CM Management LLC now owns 75,000 shares of the company’s stock worth $190,000 after buying an additional 50,000 shares during the period. 20.57% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In related news, CEO Peter Altman acquired 48,000 shares of BioCardia stock in a transaction dated Friday, September 19th. The shares were acquired at an average cost of $1.25 per share, for a total transaction of $60,000.00. Following the completion of the transaction, the chief executive officer directly owned 216,762 shares of the company’s stock, valued at $270,952.50. The trade was a 28.44% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Andrew Scott Blank acquired 288,000 shares of BioCardia stock in a transaction dated Friday, September 19th. The stock was bought at an average price of $1.25 per share, for a total transaction of $360,000.00. Following the completion of the transaction, the director directly owned 634,023 shares of the company’s stock, valued at approximately $792,528.75. This represents a 83.23% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have purchased 910,793 shares of company stock worth $1,284,021 over the last three months. 20.00% of the stock is currently owned by corporate insiders.

BioCardia Company Profile

BioCardia, Inc, a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.